Compare HLX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | ARVN |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.8M | 806.0M |
| IPO Year | 1997 | 2018 |
| Metric | HLX | ARVN |
|---|---|---|
| Price | $7.25 | $12.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 23 |
| Target Price | $10.50 | ★ $17.80 |
| AVG Volume (30 Days) | 1.4M | ★ 2.3M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 497.36 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,312,445,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | $25.67 | ★ N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $5.52 | $5.90 |
| 52 Week High | $10.21 | $25.75 |
| Indicator | HLX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 62.10 |
| Support Level | $7.24 | $11.66 |
| Resistance Level | $7.51 | $13.56 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 71.86 | 76.36 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.